(MENAFN- Baystreet) This Dividend King Just Extended Its Streak to 68 Straight Years of Increases
Costco Raises Quarterly Dividend By 14%
This High-Yielding Dividend Stock Just Boosted Its Payout by 10%
GE Aerospace Raises Dividend By 250%
Dollarama Raises Dividend By 30% Add this under widget Previous Articles Subscribe to Get Small Cap News & Alerts Baystreet Staff - Tuesday, April 16, 2024
Johnson & Johnson Reports Profit Beat And Lifts Dividend By 4.2%
Johnson & Johnson's (JNJ) first-quarter profit got a boost from strong sales of medical devices, the consumer healthcare company has reported.
Johnson & Johnson, whose financial results are viewed as a bellwether for the American healthcare sector, announced earnings per share of $2.71 U.S. versus $2.64 U.S. that was expected among analysts.
Revenue in the quarter came in at $21.38 billion U.S. compared to $21.40 billion U.S. that was forecast on Wall Street. Sales rose 2% from a year earlier.
The company's Medtech division that makes devices for surgeries, orthopedics and vision saw a rebound in sales during Q1 as demand grows for nonurgent surgeries among elderly adults.
Johnson & Johnson's medical device business generated sales of $7.82 billion U.S. in Q1, up 4% from a year ago.
The company has made growing its medical device business a priority, recently announcing a $13.10 billion U.S. acquisition of heart device firm Shockwave Medical (SWAV).
Johnson & Johnson bought two other heart device companies over the last two years, spending $16.60 billion U.S. to buy Abiomed and $400 million U.S. to buy privately held Laminar.
Along with its latest earnings print, Johnson & Johnson also said that it will increase its quarterly dividend payment to $1.24 U.S. a share, up 4.2% from $1.19 U.S. per share previously.
This marks the company's 62nd year of consecutive dividend increases, making it a“dividend king,” which is a company that has raised its dividend for 50 years or longer.
The new dividend is payable to shareholders on June 4 of this year.
Looking ahead, Johnson & Johnson narrowed its full-year guidance, saying it now expects sales of $88 billion U.S. to $88.40 billion U.S.
That compares to a previous forecast of $87.80 billion U.S. to $88.60 billion U.S. in revenue.
The company also now expects earnings of $10.57 U.S. to $10.72 U.S. a share, compared to previous guidance for $10.55 U.S. to $10.75 U.S. in per share earnings.
Johnson & Johnson's stock has declined 11% over the last 12 months to trade at $147.59 U.S. a share.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN16042024000212011056ID1108100865
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.